On March 13, the European Medicines Agency published updated information about current tenders...
On March 13, the European Medicines Agency (EMA) published updated information about current tenders—documents that explain a project and its requirements to intending bidders—worth more than £60,000 ($99,700).
The newest tender to be unveiled consists of a contract worth 1.2 million euros for the provision of information resources at the Agency itself. The closing date is June 4, 2014.
Further details about the latest tenders—which typically contain a notice inviting tenders, instructions to bidders, the conditions, form of submission, and bill of quantities—are available via this link:
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.